- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alnylam Pharmaceuticals Inc DRC (A1LN34)
79.60
+2.43(+3.15%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
79.40
79.60
52 wk Range
36.23
81.20
A1LN34 Scorecard
Full Analysis
10 analysts have revised their earnings upwards for the upcoming period
Alnylam Pharmaceuticals Inc DRC stock price live, this page displays BVMF A1LN34 stock exchange data. View the A1LN34 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alnylam Pharmaceuticals Inc DRC real time stock price chart below.
What Is the Alnylam Pharmaceuticals Inc DRC Stock Price Today?
The Alnylam Pharmaceuticals Inc DRC stock price today is 79.60.
What Is the Stock Symbol for Alnylam Pharmaceuticals Inc DRC?
The stock symbol for Alnylam Pharmaceuticals Inc DRC is "A1LN34."
What Stock Exchange Does Alnylam Pharmaceuticals Inc DRC Trade On?
Alnylam Pharmaceuticals Inc DRC is listed and trades on the B3 stock exchange.
Is Alnylam Pharmaceuticals Inc DRC a Good Stock to Buy?
Determining whether Alnylam Pharmaceuticals Inc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the A1LN34 quote. (ISIN: BRA1LNBDR003)
What Is the Alnylam Pharmaceuticals Inc DRC Stock Price Today?
The Alnylam Pharmaceuticals Inc DRC stock price today is 79.60.
What Is the Stock Symbol for Alnylam Pharmaceuticals Inc DRC?
The stock symbol for Alnylam Pharmaceuticals Inc DRC is "A1LN34."
What Stock Exchange Does Alnylam Pharmaceuticals Inc DRC Trade On?
Alnylam Pharmaceuticals Inc DRC is listed and trades on the B3 stock exchange.
Is Alnylam Pharmaceuticals Inc DRC a Good Stock to Buy?
Determining whether Alnylam Pharmaceuticals Inc DRC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the A1LN34 quote. (ISIN: BRA1LNBDR003)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
79.4079.60
52 wk Range
36.2381.20
UnlockA1LN34 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Alnylam Pharmaceuticals DRC Company Profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Compare A1LN34 to Peers and Sector
Metrics to compare | A1LN34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipA1LN34PeersSector | |
|---|---|---|---|---|
P/E Ratio | −500.4x | −4.0x | −0.6x | |
PEG Ratio | −5.37 | 0.03 | 0.00 | |
Price/Book | −11,901.3x | 2.8x | 2.6x | |
Price / LTM Sales | 15.6x | 19.5x | 3.2x | |
Upside (Analyst Target) | - | 51.8% | 44.2% | |
Fair Value Upside | Unlock | 9.6% | 7.9% | Unlock |
FAQ
What Is the Alnylam Pharmaceuticals DRC (A1LN34) Stock Price Today?
The Alnylam Pharmaceuticals DRC stock price today is 79.60.
What Stock Exchange Does Alnylam Pharmaceuticals DRC Trade On?
Alnylam Pharmaceuticals DRC is listed and trades on the B3 stock exchange.
What Is the Stock Symbol for Alnylam Pharmaceuticals DRC?
The stock symbol for Alnylam Pharmaceuticals DRC is "A1LN34."
What Is the Alnylam Pharmaceuticals DRC Market Cap?
As of today, Alnylam Pharmaceuticals DRC market cap is 204.87B.
What is Alnylam Pharmaceuticals DRC Earnings Per Share?
The Alnylam Pharmaceuticals DRC EPS is -0.579.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.